Fintel on MSN18h
RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation
Fintel reports that on March 18, 2025, RBC Capital initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform ...
Five years later, long COVID remains a frustrating medical mystery
Long COVID is arguably the most significant hangover from the pandemic. Here's what has been learned, and what remains ...
University at Buffalo19h
Faculty expert on pharmacokinetics, pharmacodynamics explains importance of field’s specialties
The University at Buffalo School of Pharmacy and Pharmaceutical Sciences has its own resident expert in the fields of ...
Targeted Oncology23h
Oncologists Favor CAR T-Cell Therapy for Early Relapsed Myeloma
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.
Center for Biosimilars1h
Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...